Cardiac rupture after myocardial infarction new insights from murine models

Cardiology in Review

Volumn 17, Issue 6, 2009, Pages 293-299

  Sane, David C ^a   Mozingo, Willis Scott ^a   Becker, Richard C ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiac rupture; Collagen; Genetic models; Matrix metalloproteinases

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA CATENIN; ALTEPLASE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGLYCAN; BLOOD CLOTTING FACTOR 13; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; FIBRINOLYTIC AGENT; GELATINASE A; GELATINASE B; GENE PRODUCT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MINOCYCLINE; MYELOPEROXIDASE; OSTEONECTIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P53; RING FINGER PROTEIN; SCAVENGER RECEPTOR A; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; UROKINASE;

BLOOD COMPONENT; CLINICAL TRIAL; CROSS LINKING; EXTRACELLULAR MATRIX; GENETIC MODEL; HEART INFARCTION; HEART LEFT VENTRICLE WALL; HEART MUSCLE CELL; HEART PAPILLARY MUSCLE; HEART RUPTURE; HEART VENTRICLE SEPTUM; HUMAN; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN DEGRADATION; REVIEW; ANIMAL; ANIMAL MODEL; BIOLOGICAL MODEL; GENETICS; METABOLISM; MOUSE; PROTEOMICS;

ANIMALS; COLLAGEN; HEART RUPTURE, POST-INFARCTION; HUMANS; MICE; MODELS, ANIMAL; MODELS, GENETIC; PROTEOMICS;

EID: 73949102956     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181bf4ab4     Document Type: Review

References (63)

1. Antman EM. ST-elevation myocardial infarction: management. In: Libby P, Bonow RD, Mann DL, et al, eds. Braunwald's Heart Disease. 8th ed. Saunders (Elsevier); 2008:1272-1275.
2. Birnbaum YB, Chamoun AJ, Anzuini A, et al. Ventricular free wall rupture following acute myocardial infarction. Coron Artery Dis. 2003;14:463-470.
3. Alonso-Orcajo N, Izquiendo-Garcia F, Simarro E. Atrial rupture and sudden death following atrial infarction. Int J Cardiol. 1994;46:82-84.
4. Arat N, Sokmen Y, Ilkay E. Isolated right ventricular rupture: a rare complication of myocardial infarction. Acta Cardiol. 2007;62:413-416.
5. Roberts WC, Morrow AG. Pseudoaneurysm of the left ventricle. An unusual sequel of myocardial infarction and rupture of the heart. Am J Med. 1967; 43:639-644.
6. Giltner A, Marelli D, Halpern E, et al. Subepicardial aneurysm with impending cardiac rupture: a case of antemortem diagnosis and review of the literature. Clin Cardiol. 2007;30:44-47.
7. Perdigao C, Andrade A, Ribeiro M, et al. Incidence and forms of clinical preparation of the various morphologic types of myocardial laceration in the acute phase of infarct. A 4 years' caseload at a coronary unit. A clinicoanatomic study of 193 successive cases. Rev Port Cardiol. 1990;9:587-598.
8. Reddy SG, Roberts WC. Frequency of rupture of the left ventricular free wall or ventricular septum among necropsy cases of fatal acute myocardial infarction since introduction since introduction of coronary care units. Am J Cardiol. 1989;63:906-911.
9. Pollak H, Nobis H, Miczoch J. Frequency of left ventricular free wall rupture complicating acute myocardial infarction since the advent of thrombolysis. Am J Cardiol. 1994;74:184-186. (Pubitemid 24219312)
10. Figueras J, Cortadellas J, Soler-Soler J. Left ventricular free wall rupture: clinical presentation and management. Heart. 2000;83:499-504.
11. Slater J, Brown RJ, Antonelli TA, et al. Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol. 2000;36:1117-1122.
12. Figueras J, Alcalde O, Barrabés JA, et al. Changes in hospital mortality rates in 425 patients with acute ST-elevation myocardial infarction and cardiac rupture over a 30-year period. Circulation. 2008;118:2783-2789.
13. Nakatani D, Sato H, Kinjo K, et al; Osaka Acute Coronary Insufficiency Study Group. Effect of successful late reperfusion by primary coronary angioplasty on mechanical complications of acute myocardial infarction. Am J Cardiol. 2003;92:785-788.
14. Kinn JW, O'Neill WW, Benzuly KH, et al. Primary angioplasty reduces risk of myocardial rupture compared to thrombolysis for acute myocardial infarction. Cathet Cardiovasc Diagn. 1997;42:151-157.
15. Gueret P, Khalife K, Jobic Y, et al. Echocardiographic assessment of the incidence of mechanical compilations during the early phase of myocardial infarction in the reperfusion era: a French multicentre prospective registry. Arch Cardiovasc Dis. 2008;101:41-47.
16. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994;343:311-322.
17. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res. 2003; 59:812-813.
18. Becker RC, Gore JM, Lambrew C, et al. A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. J Am Coll Cardiol. 1996;27:1321-1326.
19. Honan MB, Harrell FE Jr, Reimer KA, et al. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol. 1990;16:359-367.
20. Becker RC, Charlesworth A, Wilcox RG, et al. Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) study. J Am Coll Cardiol. 1995;25:1063-1068.
21. Crenshaw BS, Granger CB, Birnbaum Y, et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septol defect complicating acute myocardial infarction. Circulation. 2000;101:27-32.
22. Moreno R, López-Sendón J, García E, et al. Primary angioplasty reduces the risk of left ventricular free wall rupture compared with thrombolysis in patients with acute myocardial infarction. J Am Coll Cardiol. 2002;39:598-603.
23. Ayanian JZ, Braunwald E. Thrombolytic therapy for patients with myocardial infarction who are older than 75 years. Do the risk outweigh the benefits? Circulation. 2000;101:2224-2226.
24. Thiemann DR, Coresh J, Schulman SP, et al. Lack of benefit of intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation. 2000;101:2239-2246.
25. Maggioni AP, Maseri A, Fresco C, et al. Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. N Engl J Med. 1993;329:1442-1448.
26. Menon V, Pearte CA, Buller CE, et al. Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial. Eur Heart J. 2009;30:183-191.
27. Gao X-M, Xu Q, Kiriazia H, et al. Mouse model of post-infarct ventricular rupture: time course, strain- and gender- dependency, tensile strength and histopathology. Cardiovasc Res. 2005;65:469-477.
28. Schellings MW, Vanhoutte D, Swinnen M, et al. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med. 2009;206:113-123.
29. Yang Y, Ma Y, Han W, et al. Age-related differences in post-infarction left ventricular rupture and remodeling. Am J Physiol Heart Circ Physiol. 2008; 294:H1815-H1822.
30. Cavasin MA, Sankey SS, Yu AL, et al. Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol. 2003;284:H1560-H1569.
31. Cavasin MA, Tao ZY, Yu AL, et al. Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function. Am J Physiol Heart Circ Physiol. 2006;290:H2043-H2050.
32. Gao XM, Ming Z, Su Y, et al. Infarct size and post-infarct inflammation determine the risk of cardiac rupture in mice. Int J Cardiol. 2009;PMID 19195725.
33. Annoni G, Luvará G, Arosio B, et al. Age-dependent expressing of fibrosisrelated genes and collagen deposition in the rat myocardium. Mech Ageing Dev. 1998;101:57-72.
34. James TN. Normal and abnormal consequences of apoptosis in the human heart. Ann Rev Physiol. 1998;60:309-325.
35. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5:1135-1142.
36. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106: 55-62.
37. Hayashidani S, Tsutsui H, Ikeuchi M, et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol. 2003;285:H1229-H1235.
38. Askari AT, Brennan ML, Zhou X, et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 2003;197:615-624.
39. Tsujita K, Kaikita K, Hayasaki T, et al. Targeted deletion of class A macrophage scavenger receptor increases the risk of cardiac rupture after experimental myocardial infarction. Circulation. 2007;115:1904-1911.
40. Nahrendorf M, Hu K, Frantz S, et al. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation. 2006;113:1196-1202.
41. Sun M, Dawood F, Wen W, et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation. 2004;110:3221-3228.
42. Westermann D, Mersmann J, Melchoir A, et al. Biglycan is required for adaptive remodeling after myocardial infarction. Circulation. 2008;117: 1269-1276.
43. Shimazaki M, Nakamura K, Kii I, et al. Periostin is essential for cardiac healing after acute myocardial infarction. J Exp Med. 2008;205:295-303.
44. Ichihara S, Senbonmatsu T, Price E, et al. Targeted deletion of angiotensin ii type 2 receptor caused cardiac rupture after acute myocardial infarction. Circulation. 2002;106:2244-2249.
45. Gao XM, Dilley RJ, Samuel CS, et al. Lower risk of postinfarct rupture in mouse heart overexpressing b2-adrenergic receptors: importance of collagen content. J Cardiovasc Pharmacol. 2002;40:632-640.
46. Barandon L, Couffinhal T, Ezan J, et al. Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. Circulation. 2003;108:2282-2289.
47. Matsusaka H, Ide T, Matsushima S, et al. Targeted deletion of p53 prevents cardiac rupture after myocardial infarction in mice. Cardiovasc Res. 2006; 70:457-465.
48. Fielitz J, van Rooij E, Spencer JA, et al. Loss of muscle-specific RING-finger 3 predisposes the heart to rupture after myocardial infarction. Proc Natl Acad Sci USA. 2007;104:4377-4382.
49. Sheikh F, Chen Y, Liang X, et al. α-E-catenin inactivation disrupts the cardiomyocyte adherens junction, resulting in cardiomyopathy and susceptibility to wall rupture. Circulation. 2006;114:1046-1055.
50. van den Borne SW, Narula J, Voncken JW, et al. Defective intercellular adhesion complex in myocardium predisposes to infarct rupture in humans. J Am Coll Cardiol. 2008;51:2184-2192.
51. Matsumura S, Iwanaga S, Mochizuki S, et al. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest. 2005;115:599-609.
52. van den Borne SWM, Cleutjens JPM, Hanemaaijer R, et al. Increase matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol. 2009;18:37-43.
53. Wilson WR, Anderton M, Schwalbe EC, et al. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation. 2006;113:438-445.
54. Sane DC, Kontos JL, Greenberg CS. Roles of transglutaminases in cardiac and vascular diseases. Front Biosci. 2007;12:2530-2545.
55. Nahrendorf M, Weissleder R, Ertl G. Does Factor XIII deficiency impair wound healing after myocardial infarction? PLOS ONE. 2006;1:e48.
56. Cotena A, Gordon S, Platt N. The class A macrophage scavenger receptor attenuates CXC chemokine production and the early infiltration of neutrophils in sterile peritonitis. J Immunol. 2004;173:6427-6432.
57. Zhang C, Zhang MX, Shen YH, et al. TNF-alpha suppresses prolyl-4- hydroxylase alpha1 expression via the ASK1-JNK-NonO pathway. Arterioscler Thromb Vasc Biol. 2007;27:1760-1767.
58. Kivirikko KI, Helaakoski T, Tasanen K, et al. Molecular biology of prolyl- 4-hydroxylase. Ann NY Acad Sci. 1990;580:132-142.
59. Cleutjens JP, Verluyten MJ, Smiths JF, et al. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 1995;147:325-338.
60. Jugdutt BI, Joljart MJ, Khan MI. Rate of collagen deposition during healing and ventricular remodeling after myocardial infarction in rat and dog models. Circulation. 1996;94:94-101.
61. Factor SM, Robinson TF, Dominitz R, et al. Alterations of the myocardial skeletal framework in acute myocardial infarction with and without ventricular rupture: a preliminary report. Am J Cardiovasc Pathol. 1986;1:91-97.
62. Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation. 2003;108:1395-1403.
63. Mosher DF. Cross-linking of fibronectin to collagenous proteins. Mol Cell Biochem. 1984;58:63-68.